Introduction
============

Breast cancer is the most commonly diagnosed invasive cancer in women and the second most common cause of cancer-related mortality ([@b1-mco-0-0-1796]). In 2016, 246,660 new cases of invasive breast cancer were diagnosed in the USA, with an estimated 40,000 deaths ([@b1-mco-0-0-1796]). Significant advances in the understanding and therapeutic approaches to breast cancer have been made over the past several decades, which have led to improved patient outcomes and decreased breast cancer-related mortality ([@b2-mco-0-0-1796]). Historically, neoadjuvant therapy has been reserved for locally advanced disease as a means of reducing the tumor burden and increasing the efficacy of surgical resection ([@b3-mco-0-0-1796]). The National Surgical Adjuvant Breast and Bowel Project (NSABP) B-18 trial was one of the first to demonstrate that neoadjuvant therapy is as effective as adjuvant therapy in terms of disease-free survival (DFS) and overall survival (OS), and it provides the added benefit of increasing the rate of breast-conserving surgery ([@b4-mco-0-0-1796]). In recent years, drug development in the neoadjuvant setting has become an important research focus, allowing for a potentially more rapid investigation of tumor biology and predictive markers ([@b3-mco-0-0-1796]--[@b9-mco-0-0-1796]). Bevacizumab (Bev) was the first vascular endothelial growth factor (VEGF)-A inhibitor to be studied in breast cancer and other solid cancers ([@b10-mco-0-0-1796]--[@b14-mco-0-0-1796]), and is currently approved by the USA Food and Drug Administration (FDA) for use in several cancer types ([@b12-mco-0-0-1796]--[@b14-mco-0-0-1796]). Following provisional approval for use in metastatic breast cancer in the USA, the FDA subsequently revoked approval in November 2011, due to the risks of Bev therapy outweighing the benefits ([@b15-mco-0-0-1796],[@b16-mco-0-0-1796]). Currently, Bev is only approved for the treatment of breast cancer outside the USA. In the neoadjuvant setting, while the effects of Bev on increasing the rate of pathological complete response (pCR) are well-documented, there is currently no clear evidence on the effects of Bev on long-term outcome, or its side effects. Despite the potential benefits of Bev as adjuvant therapy, it is not approved for human epidermal growth factor receptor (HER)2-negative breast cancer patients due to its side effects. However, no study has yet compared all side effects between Bev vs. non-Bev groups. A recent meta-analysis ([@b17-mco-0-0-1796]) was undertaken to determine the effect of Bev on pCR in patients with HER2-negative breast cancer. However, that study was based on mixed randomized and non-randomized trials and included heterogeneous populations; it also did not evaluate the long-term effects or adverse effects of Bev compared with non-Bev. In view of the controversy surrounding Bev, and given the efficacy of Bev in early and advanced breast cancer but the lack of a clearly defined role in this disease, we sought to conduct a meta-analysis of large, high-quality randomized trials to compare the effect of neoadjuvant chemotherapy with and without Bev on HER2-negative breast cancer. The aim was to determine whether the achievement of higher rates of pCR with combined neoadjuvant chemotherapy and Bev compared with chemotherapy alone is associated with improved long-term survival.

Materials and methods
=====================

### Search strategy

We systematically searched for any phase II or III randomized clinical trials evaluating the effect of Bev combined with chemotherapy in the neoadjuvant setting for early or locally advanced breast cancer. The PubMed and Ovid Medline databases were searched between January 1990 and August 2016, using the search terms 'breast' AND 'neoadjuvant OR preoperative' AND 'bevacizumab OR avastin' AND 'randomized OR randomised OR random OR RCT OR trial'. After an initial search, the articles were reviewed and only large (n≥200) prospective trials on HER2-negative breast cancer were included in this meta-analysis. The PRISMA guidelines were followed for reporting and conducting this meta-analysis ([@b18-mco-0-0-1796],[@b19-mco-0-0-1796]). G. Botrus and A. Dwivedi independently analyzed the studies eligible for inclusion. Any disagreements between the two reviewers were resolved by consulting a senior investigator (Z. Nahleh).

### Inclusion and exclusion criteria

Articles were included in the present analysis based on the following critieria: i) Randomized controlled trials; ii) evaluating neoadjuvant chemotherapy treatment with and without Bev; iii) including stage I--III breast cancer; iv) HER2-negative and v) providing data on pCR, DFS and OS. Articles were excluded if they were animal studies, not written in English, based on endocrine therapy rather than chemotherapy, not published as full manuscripts, not including Bev, not randomized controlled trials, and including stage IV breast cancer cases.

### Outcome measures and data extraction

The primary endpoints for this meta-analysis were pCR, pCR in estrogen receptor (ER)/progesterone receptor (PgR)-positive cancer, and pCR in triple-negative breast cancer (TNBC). The secondary endpoints were OS, DFS and adverse events. The data extracted included year of publication, study endpoints such as pCR, pCR in ER/PgR-positive cases, pCR in triple-negative cases, DFS, OS and any-grade adverse events. Additional data on demographics or clinical characteristics were also recorded.

### Statistical analysis

The incidence and relative risk (RR) for the outcome measures and standard error (SE) for each study were compared between Bev and non-Bev. Different studies used different statistics to summarize time-to-event outcomes, such as OS and DFS. In such cases, the hazard ratio (HR) and SE of HR were computed using the suggested methods ([@b20-mco-0-0-1796]). To obtain the pooled estimate, inverse variance weights were computed for each study. Inverse variance weight adds more weight to more precise studies. After computing incidence, RR, HR, SE and weight of each outcome for each study, the heterogeneity in the studies was evaluated. I^2^ was used to evaluate heterogeneity in the studies. I^2^\>70% was considered to reflect substantial heterogeneity. The fixed-effects or random-effects model was used to compute the combined effect of Bev compared with non-Bev from different studies. When significant heterogeneity was present, the random-effects model (DerSimonian and Laird method) was used for estimating the RR/HR of outcomes in Bev compared with non-Bev. The combined effect size was summarized using either overall incidence or RR/HR, along with 95% confidence interval (CI). All analyses were conducted using Stata software, v.13.0 (StataCorp LP, College Station, TX, USA). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Study selection

The search through electronic databases using different combinations of search terms produced 279 articles. The flow chart of the study selection process ([Fig. 1](#f1-mco-0-0-1796){ref-type="fig"}) illustrates the identification of eligible articles at different review stages. A total of 5 randomized studies were ultimately included in this meta-analysis ([@b5-mco-0-0-1796],[@b21-mco-0-0-1796]--[@b25-mco-0-0-1796]). A total of 4,526 patients (2,268 treated with Bev and 2,278 without Bev) were included in the analysis. The characteristics of the individual studies are summarized in [Table I](#tI-mco-0-0-1796){ref-type="table"}. The overall incidence of the outcomes considered in the present study and the pooled effect of Bev compared with non-Bev on pCR are shown in [Table II](#tII-mco-0-0-1796){ref-type="table"}.

### Comparison of pCR between the Bev and non-Bev groups

The rate of pCR was estimated as 30% (95% CI: 21--40%), irrespective of the treatment groups (pooled estimate). The pCR range was 18--52% (21--59% in Bev vs. 17--48% in the non-Bev group), and the overall incidence of pCR was 35% with Bev vs. 26% without Bev. A relative increase of 26% in the incidence of pCR was observed in the Bev-treated group compared with the non-Bev group (RR=1.26, 95% CI: 1.15--1.38, P\<0.001). As shown in [Fig. 2](#f2-mco-0-0-1796){ref-type="fig"}, all the studies favored Bev for pCR compared with non-Bev, without significant heterogeneity (I^2^=0%). The addition of Bev to chemotherapy in the neoadjuvant setting significantly increased the rate of pCR (breast and lymph nodes) (RR=1.22, 95% CI: 1.10--1.36, P\<0.001) compared with treatment without Bev. In TNBC, there was a 30% relative increase in the incidence of pCR (RR=1.30, 95% CI: 1.16--1.45, P\<0.001) in patients treated with Bev vs. the non-Bev group. In addition, in ER/PgR+ cases, there was a 27% relative increase in the incidence of pCR (RR=1.27, 95% CI: 1.13--1.42, P\<0.001) in patients treated with Bev compared with the non-Bev group ([Table III](#tIII-mco-0-0-1796){ref-type="table"}).

### Comparison of OS and DFS between the Bev and non-Bev groups

Of the 5 studies analyzed, 4 reported the DFS and OS status by treatment groups ([Figs. 3](#f3-mco-0-0-1796){ref-type="fig"} and [4](#f4-mco-0-0-1796){ref-type="fig"}). Patients treated with Bev exhibited no difference in the risk of recurrence (I^2^=35.7%; HR=0.97, 95% CI: 0.85--1.11, P=0.684) without presence of significant heterogeneity (P=0.198); however, a trend towards reducing the risk of death (I^2^=64%; HR=0.90; 95% CI: 0.76--1.06, P=0.194) was noted, without substantial heterogeneity in the effect (I^2^=64, P=0.04).

### Comparison of adverse events between the Bev and non-Bev groups

The incidence of grade 3 and 4 adverse events was compared between treatment groups and the results are summarized in [Table IV](#tIV-mco-0-0-1796){ref-type="table"}. Individual reported adverse events were compared across studies. Some adverse events were found to be significantly more common in the Bev group compared with the non-Bev group, including hypertension (RR=5.36), mucositis (RR=5.23), peripheral neuropathy (RR=1.75), febrile neutropenia (RR=1.71), infection (RR=1.68), hand-foot syndrome (RR=1.57) and neutropenia (RR=1.06).

Discussion
==========

To the best of our knowledge, this is the first meta-analysis addressing the long-term outcomes of Bev in combination with chemotherapy in the neoadjuvant treatment of HER2-negative breast cancer. The addition of Bev to chemotherapy was found to significantly increase the incidence of pCR (breast and lymph nodes) compared with treatment without Bev in ER/PgR-positive and triple-negative cases. Although the addition of Bev to chemotherapy did not translate into a significant difference in DFS, it exhibited a trend towards improving OS, but without reaching statistical significance. Despite the heterogeneity in reporting adverse events among the trials, there was no significant difference in the incidence of grade 3 and 4 adverse events between the Bev and non-Bev groups. However, patients treated with Bev more commonly experienced hypertension, mucositis, peripheral neuropathy and neutropenia compared with those treated without Bev. These findings are consistent with the adverse events associated with the use of Bev, as the most common grade 3/4 adverse events include hypertension followed by mucositis.

The results of the present study are consistent with the findings from another recent meta-analysis that included 9 studies and reported the efficacy of Bev with chemotherapy compared with Bev without chemotherapy in terms of pCR as the primary endpoint of interest, without assessing long-term survival outcome ([@b17-mco-0-0-1796]). However, there were notable differences between the two studies: Cao *et al* ([@b17-mco-0-0-1796]), combined studies with both HER2-negative and HER2-positive breast cancer and included mostly preliminary findings, without examining the long-term effects of Bev. By contrast, the present analysis included completed randomized trials, excluded HER2-positive breast cancer, and reported long-term survival data. As regards to efficacy, we also observed some differences. The overall efficacy of Bev in terms of pCR in HER2-negative patients was found to be slightly lower in our analysis, which had a larger sample size, compared with the one reported by Cao *et al* ([@b17-mco-0-0-1796]).

The results of our analysis were consistent with the reported outcome on pCR in the 5 neoadjuvant trials considered ([@b5-mco-0-0-1796],[@b21-mco-0-0-1796]--[@b25-mco-0-0-1796]). However, there were also certain variations. In our analysis, an overall relative increase of 26% in the incidence of pCR was observed in the Bev group compared with the non-Bev group, which is very similar to the pCR reported in the studies analyzed ([@b5-mco-0-0-1796],[@b21-mco-0-0-1796]--[@b23-mco-0-0-1796]). One study ([@b24-mco-0-0-1796]) that included primarily higher-risk patients with locally advanced and inflammatory breast cancer (S0800) reported a slightly higher RR of pCR in the Bev group compared with the non-Bev group, as opposed to the other 4 studies and the pooled effect obtained in this study. The variation observed in the S0800 study may be due to its comparatively smaller size relative to the other 4 studies considered in this meta-analysis.

A notable difference in our analysis was that the benefit of Bev treatment in increasing pCR rate was observed in both the triple-negative (30% increase in relative incidence of pCR, 11% absolute benefit) as well as in the ER/PgR-positive groups (26% increase in relative incidence of pCR, 9% absolute benefit). The ARTemis trial ([@b5-mco-0-0-1796]) reported a 6% adjusted absolute increase in the incidence of pCR after addition of Bev to standard neoadjuvant therapy compared with the non-Bev group (26 vs. 19% overall (95% CI: 0.1--12.1); P=0.02), but the efficacy was restricted to the ER-negative/HER-2-negative subgroup defined as Allred 0--2 (15% absolute improvement) and the ER weakly positive group (Allred 3--5) (20% absolute improvement), whereas there was no benefit in the ER strongly positive group (Allred 6--8) (absolute decrease of 1%). Similarly, in the GeparQuinto study ([@b25-mco-0-0-1796]), the addition of Bev significantly increased the incidence of pCR in TNBC (11.4% absolute benefit), in contrast to only 0.1% in the hormone receptor-positive subgroup. The CALGB 40603 study ([@b21-mco-0-0-1796]), a randomized phase II trial limited to stage II--III TNBC reported a significant increase in pCR incidence in the Bev group compared with the non-Bev group (59 vs. 48%, respectively; P=0.009). The S0800 trial ([@b24-mco-0-0-1796]) demonstrated a significant increase in pCR rate with the addition of Bev in both the ER/PgR-positive and triple-negative groups, but the increase only reached statistical significance in the TNBC group. The findings of the NSABP B-40 trial ([@b22-mco-0-0-1796]) were somewhat contradictory, showing a significant increase in the number of patients achieving pCR in the hormone-positive group (23.2 vs. 15.1%, P=0.007) but not in the triple-negative group (51.5 vs. 47.1%, P=0.34).

The apparent discordance between the various studies may be explained by differences in study design and definitions of hormone receptor-positive disease. An ER/PgR-positive disease was defined as \>10% positive cells for either ER or PgR in GeparQuinto ([@b25-mco-0-0-1796]) and CALGB 40603 ([@b21-mco-0-0-1796]), while a 1% cutoff was used in S0800 ([@b24-mco-0-0-1796]) and NSABP B-40 ([@b22-mco-0-0-1796]), and an Allred score \>2 was used in ARTemis trial to identify ER/PgR-positive patients ([@b5-mco-0-0-1796]), a definition similar to that of NSABP B-40 and S0800. It is, therefore, plausible that the increased proportion of patients who achieved a pCR in the ER/PgR-positive group in NSABP B-40 and S0800 resulted from patients with low ER/PgR scores who were excluded by GeparQuinto and CALGB 40603. Despite these differences, however, our analysis suggests that the benefits from Bev may not be limited to TNBC cases.

Our meta-analysis failed to demonstrate that the addition of Bev in the neoadjuvant setting improved DFS. This was not unexpected, considering the small absolute increment noted in pCR (11% for TNBC and 9% for ER/PgR-positive cases). This finding is consistent with the results reported from the 5 considered studies. The association between pCR and event-free survival (EFS) has been quite challenging to elucidate ([@b26-mco-0-0-1796]). Berry and Hudis analyzed the potential causes for the discordance between pCR and EFS ([@b26-mco-0-0-1796]). They noted the difficulty to demonstrate a significant correlation when the treatment effect is being measured based on a small number of clinical trials or trial subsets, particularly given the small treatment differences in pCR rates in the trials and the inherent variability in reassembling patients into trials and treatment arms. However, the neoadjuvant approach to future drug development may still have a potentially significant role, should future phase 3 trials implement specific novel adaptive designs, such as the use of interim by-treatment information regarding pCR and EFS and adapting to accumulating information in the trial, among other strategies ([@b26-mco-0-0-1796]).

In our analysis, the small change in pCR rates combined with the different combinations of chemotherapy regimens used, different disease stages, discontinuation of Bev after surgery and possible rebound angiogenesis ([@b27-mco-0-0-1796]), as well as the varied median follow-up periods, would be plausible explanations for the lack of effect regarding DFS. However, the overall effect of Bev on OS exhibited a positive trend favoring Bev compared with non-Bev. This positive effect on OS was largely attributed to two trials ([@b22-mco-0-0-1796],[@b24-mco-0-0-1796]), while a lack of effect of Bev on OS was reported in one trial ([@b5-mco-0-0-1796]).

The results of the present meta-analysis are consistent with two large phase III postoperative trials indicating absence of a DFS and OS advantage from Bev when used in HER2-negative breast cancer ([@b28-mco-0-0-1796],[@b29-mco-0-0-1796]). The E5103 trial recruited 4,994 patients with HER2-negative disease and both hormone receptor-positive and -negative disease ([@b29-mco-0-0-1796]), while the BEATRICE trial enrolled 2,591 patients with only TNBC ([@b28-mco-0-0-1796]). In both trials, Bev was added to chemotherapy. After completing chemotherapy, the patients were randomly assigned to receive or not receive single-agent Bev for a total duration of 1 year. Neither trial showed an improvement in DFS or OS with the addition of 1 year of Bev to the adjuvant chemotherapy. Thus, the addition of continuous Bev treatment after surgery cannot be fully supported by the outcome of those trials. On the other hand, the positive trend in OS favoring Bev compared with chemotherapy without Bev noted in our analysis requires further investigation. In light of the NSABP-B40 data, it may be hypothesized that the benefit of Bev is most pronounced when used in a combined pre- and postoperative setting. When used as such, Bev, a targeted anti-angiogenic agent, may be most useful in treating relatively large or more locally advanced tumors in the breast and lymph nodes, where high dependence on angiogenesis may be at play. This activity is reflected by the increased pCR with the use of Bev in the present meta-analysis, and particularly in trials including locally advanced and inflammatory tumors, such as the S0800 ([@b24-mco-0-0-1796]). The continuation of Bev after surgery may provide an additional benefit by suppressing possible rebound tumor cell growth ([@b27-mco-0-0-1796]).

As noted above, there was some heterogeneity observed for reporting adverse events across the different studies. In the CALGB 40603 study ([@b21-mco-0-0-1796]), 12% of patients administered Bev, with or without carboplatin, stopped treatment early due to toxicity. Similarly, 14% of patients receiving Bev in the ARTemis ([@b5-mco-0-0-1796]) trial and 12% of patients in the GeparSixto trial ([@b23-mco-0-0-1796]) stopped treatment early due to the toxicity. The most common grade 3/4 adverse events included hypertension followed by mucositis, peripheral neuropathy, febrile neutropenia, infection and hand-foot syndrome, and the incidence was increased with Bev compared with non-Bev. Other studies have also demonstrated that Bev use is associated with increased incidence of grade 3 and 4 hypertension and mucositis. However, an increase in grade 3 and 4 left ventricular systolic dysfunction, thromboembolic events, bleeding and postoperative complications with Bev was not reported in the individual studies included in our analysis ([@b5-mco-0-0-1796],[@b7-mco-0-0-1796],[@b21-mco-0-0-1796],[@b23-mco-0-0-1796]--[@b25-mco-0-0-1796]).

One of the major limitations in the clinical applicability of Bev and potentially other similar agents in breast cancer is the current lack of information regarding specific prognostic markers correlated with Bev efficacy. Prognostic markers for Bev therapy have been studied in other solid cancers, and it has been suggested that improved efficacy of Bev in metastatic colorectal cancer is correlated with specific endothelial nitric oxide synthase (eNOS) polymorphisms ([@b30-mco-0-0-1796]). The greatest improvement in progression-free survival was associated with the haplotype homozygous for eNOS VNTR 4bb and eNOS + 894 TT. Various VEGFR1 and VEGFA single-nucleotide polymorphisms (SNPs) have also been implicated as prognostic markers for Bev therapy ([@b31-mco-0-0-1796],[@b32-mco-0-0-1796]). The recent findings of the ANGIOMET study demonstrated that VEGFA SNP rs3025039 and VEGFR1 SNP rs9582036 were associated with reduced OS in patients treated with Bev for non-small-cell lung cancer ([@b32-mco-0-0-1796]). Lower basal VEGF levels were also associated with better patient outcomes. This is in agreement with earlier reports suggesting that high levels of VEGF are correlated with increased vascular count and density, which may result in greater tumor growth ([@b33-mco-0-0-1796]). In the CALGB 40603 trial, the investigators studied how intrinsic subtype assigned by PAM50 and other gene signatures affected the impact of Bev on pCR rates in TNBC ([@b34-mco-0-0-1796]). A significant benefit of Bev was noted in the basal-like subtype, yielding a more than double the odds of achieving pCR. In basal-like tumors, pCR was 64% with Bev vs. 45% without Bev (odds ratio = 2.15, P=0.0009). However, for the other subtypes, the rates were 43 and 60%, respectively (odds ratio = 0.50, P=0.25), indicating a possible trend toward worse outcome when Bev was added ([@b33-mco-0-0-1796]). Furthermore, higher levels of expression of any of the following immune signatures, mRNA signatures for high proliferative rate, low estrogen signaling, high TP53 mutation, and an increase in the number of tumor-infiltrating lymphocytes, were associated with higher pCR rates. High proliferation rate, low estrogen expression, or high TP53-mutation signatures, in particular, were predictive of higher pCR rates overall, and a greater pCR benefit from the addition of Bev. These findings suggest that, even within TNBC, there are biologically defined patient subsets that may benefit from this agent. Further research is necessary, however, to confirm and validate reliable predictive and prognostic markers of Bev efficacy for the treatment of breast cancer.

In summary, the present meta-analysis confirms the benefit of Bev combined with chemotherapy compared with chemotherapy alone in the neoadjuvant treatment of HER2-negative breast cancer. This benefit in pCR is quite intriguing, as it does not translate into a long-term DFS or definitive OS advantage. Therefore, in the absence of specific predictive or efficacy markers, the use of non-targeted Bev in the treatment of an unselected breast cancer patient population cannot be justified at this time. This is particularly true in view of the adverse effect profile associated with the use of Bev. Further research is warranted for the pre-treatment identification of predictive and prognostic markers to identify the subsets of breast cancer patients who are most likely to benefit from Bev therapy. However, the premature dismissal of this effective agent in the treatment armamentarium of breast cancer is not recommended. Should a breast cancer patient subset be identified that may benefit from the addition of Bev, the studies included in this analysis can be revisited and confirmatory studies conducted using collected stored tissue samples. Furthermore, predictors of the efficacy of Bev, if identified in ongoing or future translational studies, may prompt new trials of this drug in better defined patient subgroups.
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###### 

Characteristics of included studies.

  Authors                     Sikov *et al*, CALGB 40603 ([@b21-mco-0-0-1796])                                                                                                    Earl *et al*, ARTemis trial ([@b5-mco-0-0-1796])                                             Bear *et al*, NSABP B-40 ([@b22-mco-0-0-1796])                                       von Minckwitz *et al*, GeparQuinto ([@b25-mco-0-0-1796])                           Nahleh *et al*, S0800 ([@b24-mco-0-0-1796])
  --------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------
  Year                        2015                                                                                                                                                2015                                                                                         2012                                                                                 2012                                                                               2016
  Journal                     JCO                                                                                                                                                 Lancet Oncology                                                                              NEJM                                                                                 NEJM                                                                                 BCRT
  Study type                  2×2 factorial randomized, open-label, phase II trial                                                                                                Randomized, open-label, phase III trial                                                      3×2 factorial randomized, open-label, phase III trial                                Randomized, open-label, phase III trial                                            Randomized, open-label, phase II trial
  Sample size (Bev/non-Bev)   443 (222/221)                                                                                                                                       781 (388/393)                                                                                1,166 (591/595)                                                                      1,925 (969/956)                                                                    211 (98/113)
  Patient population          Early-stage and HER2-negative                                                                                                                       Early-stage and HER2-negative                                                                HER2-negative                                                                        HER2-negative                                                                      Locally advanced and HER2-negative
  Inclusion criteria          Operable, previously untreated, clinical stage II--III non-inflammatory invasive breast cancer, with ER and PgR expression ≤10% and HER2-negative   Early-stage invasive breast cancer; radiological tumor size \>20 mm ± axillary involvement   Operable breast cancer                                                               Previously untreated, unilateral or bilateral, primary invasive breast carcinoma   Previously untreated, clinical stage IIB-IIIC HER2-negative breast carcinoma and known hormone receptor status
  Age range, years            40--59                                                                                                                                              18--50                                                                                       18--49                                                                               24--78                                                                             22--75
  Recruitment time            May 2009-August 2012                                                                                                                                May 2009-January 2013                                                                        January 2007-June 2010                                                               August 2011-December 2012                                                          May 2010-September 2012
  Primary outcome             pCR of the breast                                                                                                                                   pCR of the breast and axilla                                                                 pCR of the breast                                                                    pCR of the breast                                                                  pCR of the breast and axilla
  Secondary outcome           pCR of the breast and axilla and side effects                                                                                                       pCR of the breast, DFS, OS and adverse events                                                pCR of the breast and axilla and adverse events                                      pCR of the and axilla, DFS, OS and adverse events                                  DFS, OS and adverse events
  Treatment group             Arm (1,2)-ddAC ± Bev; Arm (3,4)-wPcarbo followed by ddAC + Bev                                                                                      D-FEC vs. Bev + D-FEC                                                                        Arm (1,2)-Doc ± Bev; Arm (3,4)-Doc + capecitabine ± Bev; Arm (5,6)-Doc + Gem ± Bev   Paclitaxel + liposomal doxorubicin + Bev ± Carbo                                   Arm (1)-weekly nab-paclitaxel and Bev followed by ddAC; Arm (2)-nab-paclitaxel followed by ddAC; Arm (3)-ddAC followed by nab-paclitaxel
  Median follow-up, months    39                                                                                                                                                  40                                                                                           N/A                                                                                  28                                                                                 36

CALGB, Cancer and Leukemia Group B; NSABP, National Surgical Adjuvant Breast and Bowel Project; JCO, Journal of Clinical Oncology; NEJM, New England Journal of Medicine; BCRT, Breast Cancer Research and Treatment; ddAC, dose-dense adriamycin and cyclophosphamide; Doc, docetaxel; Gem, gemcitabine; wP, weekly paclitaxel; Bev, bevacizumab; wPCarbo, weekly paclitaxel and carboplatin; D-FEC, docetaxel, 5-fluorouracil, epirubicin and cyclophosphamide; AC, adriamycin and cyclophosphamide; ER, estrogen receptor; PgR, progesterone receptor; pCR, pathological complete response; DFS, disease-free survival; OS, overall survival; N/A, not available.

###### 

Pooled estimate of pCR by subgroups.

                                            95% CI   
  --------------------------- ------ ------ -------- ------
  pCR                         98.1   0.30   0.21     0.40
    In breast + lymph nodes   98.1   0.27   0.17     0.36
    In ER/PgR^+^ cases        0.0    0.50   0.48     0.52
    In TNBC                   95.3   0.53   0.44     0.62

CI, confidence interval; I^2^, measure of heterogeneity; pCR, pathological complete response; ER, estrogen receptor; PgR, progesterone receptor; TNBC, triple-negative breast cancer.

###### 

Pooled estimate of pCR in Bev compared with non-Bev.

                                         95% CI          
  ------------------------- ----- ------ -------- ------ ---------
  pCR                       0.0   1.26   1.15     1.38   \<0.001
  In breast + lymph nodes   0.0   1.22   1.10     1.36   \<0.001
  In ER/PgR^+^ cases        8.9   1.27   1.13     1.42   \<0.001
  In TNBC                   0.0   1.30   1.16     1.45   \<0.001

CI, confidence interval; I^2^, measure of heterogeneity; pCR, pathological complete response; ER, estrogen receptor; PgR, progesterone receptor; TNBC, triple-negative breast cancer.

###### 

Risk of grade3/4 adverse events in Bev compare with non-Bev.

                                        95% CI          
  ----------------------- ------ ------ -------- ------ ---------
  Grade 1/2               0.0    1.00   0.94     1.06   0.915
  Grade 3/4               93.9   1.14   0.90     1.44   0.280
  Leukopenia              0      1.02   0.74     1.41   0.882
  Neutropenia             37.5   1.06   1.01     1.11   0.024
  Thrombocytopenia        4      1.05   0.61     1.81   0.849
  Hemoglobin              50.9   1.32   0.70     2.50   0.392
  Febrile neutropenia     50.9   1.71   1.39     2.11   \<0.001
  Nausea                  0      0.91   0.65     1.30   0.613
  Vomiting                73.4   0.80   0.53     1.21   0.293
  Mucositis               72.6   5.23   3.70     7.40   \<0.001
  Diarrhea                50.1   0.84   0.60     1.18   0.316
  Hypertension            74.1   5.36   3.51     8.19   \<0.001
  Peripheral neuropathy   3.2    1.75   1.086    2.81   0.021
  Fatigue                 0      1.20   0.95     1.52   0.136
  Pain                    22.4   1.11   0.71     1.73   0.665
  Infection               25.2   1.68   1.35     2.09   \<0.001
  Thrombosis              0      1.43   0.91     2.24   0.119
  Hand-foot syndrome      0      1.57   1.04     2.38   0.034

CI, confidence interval; I^2^, measure of heterogeneity; RR, relative risk; Bev, bevacizumab.
